Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-Term Safety Extension Study of ACTIMMUNE (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia

Next Previous
X
Search
Trial Profile

Long-Term Safety Extension Study of ACTIMMUNE (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon gamma-1b (Primary)
  • Indications Friedreich's ataxia
  • Focus Adverse reactions
  • Acronyms STEADFAST Long-Term Safety Extension
  • Sponsors Horizon Therapeutics plc

    • Most Recent Events

    • 24 Feb 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2017.
    • 24 Feb 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2017.
    • 08 Dec 2016 Status changed from recruiting to discontinued. According to a Horizon Pharma media release, the company in conjunction with the independent Data Safety Monitoring Board, the principal investigator and the Friedreich's Ataxia Research Alliance (FARA) Collaborative Clinical Research Network (CCRN) in FA, has determined that, based on the results from a parent phase III study (profile 700251922), the FA (Friedreich's ataxia) development program will be discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top